

NDA 020402/S-058

SUPPLEMENT APPROVAL

Haleon US Holdings LLC
Attention: Alberto Jose Garzon
Senior Regulatory Affairs Manager, US Regulatory
184 Liberty Corner Road, Suite 200
Warren, NJ 07059

Dear Alberto Jose Garzon:

Please refer to your supplemental new drug application (sNDA) dated and received September 10, 2024, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Advil Liqui-Gels and Advil Migraine (ibuprofen) capsules, 200 mg.

This prior approval supplemental new drug application provides for the addition of following new stock-keeping units (SKUs) described as:

- Advil Liqui-Gels 160-count (2 x 80-count) twin pack outer container (carton)
- Advil Liqui-Gels minis 160-count (2 x 80-count) twin pack outer container (carton)

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

LABELING

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The FPL must be in the “Drug Facts” format (21 CFR 201.66), where applicable and must be identical to the following labeling:

Submitted Labeling	Date Submitted
Advil Liqui-Gels 160-count (2 x 80-count) twin pack outer container (carton)	December 20, 2024
Advil Liqui-Gels minis 160-count (2 x 80-count) twin pack outer container (carton)	December 20, 2024

The FPL should be submitted electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*.¹ For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 020402/S-058.**” Approval of this submission by FDA is not required before the labeling is used.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at FDA.gov.² Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Myla Dellupac, Regulatory Project Manager, at Myla.Dellupac@fda.hhs.gov or 301-837-7461.

Sincerely,

{See appended electronic signature page}

Nushin Todd, MD, PhD
Director
Division of Nonprescription Drugs I
Office of Nonprescription Drugs
Office of New Drugs
Center for Drug Evaluation and Research

¹ We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

² <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

NDA 020402/S-058

Page 3

ENCLOSURE(S):

- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

NUSHIN F TODD
01/08/2025 09:10:41 AM